Investors Urged to Contact Levi & Korsinsky for Information Before December 26, 2025 - DexCom, Inc. (DXCM)

November 03, 2025 4:08 PM EST | Source: Levi & Korsinsky, LLP

New York, New York--(Newsfile Corp. - November 3, 2025) - If you suffered a loss on your DexCom, Inc. (NASDAQ: DXCM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form-2?prid=175325&wire=5&utm_campaign=5

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7091/273034_398820_logo.jpg

THE LAWSUIT: A class action securities lawsuit was filed against DexCom, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between July 26, 2024 and September 17, 2025.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) DexCom had made material design changes to The Company's glucose monitoring products, the G6 and G7, unauthorized by the U.S. Food and Drug Administration; (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (v) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (vi) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

WHAT'S NEXT? If you suffered a loss in DexCom, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form-2?prid=175325&wire=5&utm_campaign=5 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273034

info